ACRIVON THERAPEUTICS, INC.

Analyst Reco. Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Market Closed - Nasdaq Other stock markets 15:59:45 2024-05-29 EDT			5-day change	1st Jan Change
7.5 ^USD	-2.85%		-12.49%	+52.44%

05-14	Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-30	North American Morning Briefing : More Earnings -2-	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral	04-29	MT
Piper Sandler Adjusts Price Target on Acrivon Therapeutics to $30 From $26, Keeps Overweight Rating	04-25	MT
Ladenburg Thalmann Cuts Price Target on Acrivon Therapeutics to $14 From $18, Maintains Buy Rating	04-05	MT
JMP Securities Starts Acrivon Therapeutics With Market Outperform Rating, $14 Price Target	03-01	MT
Maxim Initiates Acrivon Therapeutics at Buy Rating With $24 Price Target	23-10-05	MT
Oppenheimer Initiates Coverage on Acrivon Therapeutics With Outperform Rating, $25 Price Target	23-06-02	MT
BMO Capital Initiates Acrivon Therapeutics at Outperform With $25 Price Target	23-05-08	MT
HC Wainwright Initiates Coverage on Acrivon Therapeutics With Buy Rating, $24 Price Target	23-04-20	MT
Jefferies Starts Acrivon Therapeutics at Buy With $17 Price Target	22-12-12	MT
Piper Sandler Starts Acrivon Therapeutics at Overweight With $25 Price Target	22-12-12	MT
Cowen Starts Acrivon Therapeutics at Outperform	22-12-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer